Triglav Skladi D.O.O. Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Triglav Skladi D.O.O. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,500 shares of the medical research company's stock, valued at approximately $1,081,000.

Other institutional investors have also added to or reduced their stakes in the company. Synergy Asset Management LLC bought a new stake in IQVIA in the 4th quarter valued at $33,000. GKV Capital Management Co. Inc. bought a new stake in shares of IQVIA during the 4th quarter valued at $39,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the 4th quarter valued at $44,000. Zions Bancorporation N.A. lifted its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in shares of IQVIA during the 4th quarter valued at $60,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Wall Street Zen downgraded IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. JPMorgan Chase & Co. lowered their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday. Finally, HSBC cut IQVIA from a "buy" rating to a "hold" rating and lowered their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $228.14.

IQVIA Trading Up 0.4%

Shares of IQV stock traded up $0.61 on Thursday, hitting $137.90. The company had a trading volume of 3,034,505 shares, compared to its average volume of 1,551,125. The firm has a market cap of $23.86 billion, a P/E ratio of 18.39, a P/E/G ratio of 1.99 and a beta of 1.34. The stock's 50-day moving average is $157.30 and its two-hundred day moving average is $184.65. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a twelve month low of $135.77 and a twelve month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.54 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.